Daily filing brief

6 Most Important Filings — 24 June 2026

A concise list of today's most consequential exchange filings, selected for relevance and impact.

  1. Aye Finance Ltd2:30 pm IST

    Ind-Ra upgrades Aye Finance to IND A+/Stable; CP to IND A1+

    Rating actions and instrument details

    • Issuer rating upgraded to IND A+/Stable from IND A/Stable.
    • CP rating raised to IND A1+ from IND A1.
    • Bank loan facilities upgraded to IND A+/Stable.
    • Non-convertible debentures upgraded to IND A+/Stable; size reduced to INR 12,963.09m.
    • Outlook remains Stable; upgrade driven by capitalisation and funding diversification.

    Rationale, liquidity and financials

    • IPO-driven capitalisation improved tangible net worth to INR 24.75b.
    • AUM stands at INR 70.44b; secured loans ~60% of portfolio.
    • Adequate liquidity with unencumbered cash around INR 7.6b; diversified funding.
    • Covenant breaches exist in 9.2% of total borrowings; waivers have been obtained.
    • NPA 4.77%; leverage 2.03x; Tier 1 42.24%.

    Outlook and sensitivities

    • Outlook: Stable.
    • Material changes since last: issuer and CP upgrades; NCD size reduced.
    • Upgrade possible with continued growth, diversification, and stable long-term funding.
    • Downgrade risk if funding dries up, leverage exceeds 4x, or asset quality deteriorates.
    Read the original filing
  2. Biocon Ltd2:04 pm IST

    Duopharma Biotech secures insulin tenders from Malaysia MoH; Biocon unit to supply insulin products

    Key contract wins

    • Duopharma Biotech via Duopharma (M) Sendirian Berhad secures insulin contracts from Malaysia MoH worth over MYR 225 million.

    Contract details

    • 3-year contract for human insulin: ~ MYR 155.27 million.
    • 2-year contracts for insulin glargine: ~ MYR 18 million; insulin aspart: ~ MYR 52.5 million.

    Biocon role

    • Biocon Sdn. Bhd. to supply short-acting insulin, insulin glargine, and insulin aspart to Duopharma (M) Sendirian Berhad.

    Strategic context

    • Johor facility enables scale manufacturing and broader patient access in Malaysia.
    Read the original filing
  3. Shilpa Medicare Ltd2:33 pm IST

    Shilpa Biologicals commissions ADC GMP manufacturing facility; fully operational with GMP qualification underway

    Facility update and strategic context

    • Shilpa Biologicals Pvt Ltd, a Shilpa Medicare subsidiary, commissioned an ADC GMP manufacturing facility.
    • Facility is fully operational; GMP qualification protocols are underway.
    • Designed to meet US FDA, EMA, and major health authority requirements.
    • End-to-end ADC Drug Substance development and manufacturing including payload synthesis, linker development, mAb production, conjugation, purification.
    • Positions Shilpa as a cost-competitive, fully integrated ADC CDMO partner.
    • Supports Shilpa Medicare's strategy to expand high-potency biologics and oncology drug substances.
    Read the original filing
  4. Shri Bajrang Alliance Ltd4:04 pm IST

    Credit rating downgraded for Shri Bajrang Alliance Limited bank facilities to IVR BBB-/Stable

    Rating action and details

    • Long-term rating downgraded to IVR BBB-/Stable for Rs 25 crore bank facilities.
    • Agency: Infomerics Valuation and Rating Ltd; rating letter dated 23 June 2026.
    • Rating valid for one year from the rating committee date.
    • Rationale cites FY26 developments and review of operational and financial performance.
    • Instrument: bank facilities (cash credit) Rs 25 crore; facility with HDFC Bank.
    • Outlook: Stable; no change beyond the assigned Stable outlook.
    • Surveillance: annual review; NDS and quarterly data to be provided.
    Read the original filing
  5. AXIS Bank Ltd4:29 pm IST

    S&P Global Ratings assigns BB- to Axis Bank Gift City Branch AT1 Notes and BBB to GMTN Senior Notes

    Rating actions and instruments

    • BB- assigned to Axis Bank Gift City Branch AT1 Notes under GMTN.
    • BBB assigned to Axis Bank Gift City Branch Senior Notes under GMTN.
    • Issuer Rating BBB for Axis Bank Gift City Branch.

    Instruments/Facilities Rated

    • GMTN AT1 Notes – BB-.
    • GMTN Senior Notes – BBB.
    • Issuer Rating BBB (Gift City Branch).

    Rating Agency

    • S&P Global Ratings.

    Rationale

    • Rationale letters attached; detailed rationale not included in this chunk.

    Material changes

    • New ratings issued; no prior rating changes disclosed in this chunk.
    Read the original filing
  6. AXIS Bank Ltd3:07 pm IST

    Moody's assigns Baa3 rating with Stable outlook to Axis Bank GMTN senior notes

    Rating Action Details

    • Moody's assigns Baa3 rating with Stable Outlook to Axis Bank GMTN senior notes.
    • GMTN programme overall; Series 10 notes USD 300m rated Baa3 with Stable Outlook.
    • Rationale letter attached; explicit rating sensitivities are not disclosed.
    Read the original filing